Last reviewed · How we verify
Placebo to Palonosetron
Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy.
Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting caused by chemotherapy. Used for Prevention of acute nausea and vomiting caused by moderately emetogenic chemotherapy, Prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
At a glance
| Generic name | Placebo to Palonosetron |
|---|---|
| Sponsor | Helsinn Healthcare SA |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Palonosetron is a selective serotonin 5-HT3 receptor antagonist that has a longer half-life compared to other 5-HT3 antagonists, allowing for once-daily dosing. This mechanism of action helps to prevent the activation of the 5-HT3 receptors in the central nervous system, which are responsible for nausea and vomiting.
Approved indications
- Prevention of acute nausea and vomiting caused by moderately emetogenic chemotherapy
- Prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy
Common side effects
- Headache
- Dizziness
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery (PHASE4)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
- Effect of SAR302503 on ECG Activity in Patients With Solid Tumors (PHASE1)
- Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC) (PHASE2)
- Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Palonosetron CI brief — competitive landscape report
- Placebo to Palonosetron updates RSS · CI watch RSS
- Helsinn Healthcare SA portfolio CI